平台上演GLP-1药物“三强争霸”，中国首款GLP-1减重药物于美团线上首发

广州日报2025-07-04

美团又一次成为GLP-1减重药物的首发平台。7月3日，刚刚获批的减重创新药物玛仕度肽注射液（商品名：信尔美®）在美团医药健康旗下美团自营大药房首发上线。　　对此，专家提醒：购买、用药仍需遵医嘱或在专业药师指导下进行。　　据悉，这是继口服版司美格鲁肽和替尔泊肽之后，美团又一次承接GLP-1药物的全网独家首发，三款减重药物也将于美团平台内上演“三强争霸”。　　凭借“产品+服务”的创新保障模式和大面积...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2548361404?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-04 17:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2548361404","market":"us","top_or_hot":-1,"title":"平台上演GLP-1药物“三强争霸”，中国首款GLP-1减重药物于美团线上首发","media":"广州日报","content":"<div>\n<p>美团又一次成为GLP-1减重药物的首发平台。7月3日，刚刚获批的减重创新药物玛仕度肽注射液（商品名：信尔美®）在美团医药健康旗下美团自营大药房首发上线。　　对此，专家提醒：购买、用药仍需遵医嘱或在专业药师指导下进行。　　据悉，这是继口服版司美格鲁肽和替尔泊肽之后，美团又一次承接GLP-1药物的全网独家首发，三款减重药物也将于美团平台内上演“三强争霸”。　　凭借“产品+服务”的创新保障模式和大面积...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202507043448631272.html\">网页链接</a>\n\n</div>\n","source":"stock_eastmoney","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>平台上演GLP-1药物“三强争霸”，中国首款GLP-1减重药物于美团线上首发</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n平台上演GLP-1药物“三强争霸”，中国首款GLP-1减重药物于美团线上首发\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-04 17:08 北京时间&nbsp;&nbsp;&nbsp;<a href=http://finance.eastmoney.com/a/202507043448631272.html><strong>广州日报</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>美团又一次成为GLP-1减重药物的首发平台。7月3日，刚刚获批的减重创新药物玛仕度肽注射液（商品名：信尔美®）在美团医药健康旗下美团自营大药房首发上线。　　对此，专家提醒：购买、用药仍需遵医嘱或在专业药师指导下进行。　　据悉，这是继口服版司美格鲁肽和替尔泊肽之后，美团又一次承接GLP-1药物的全网独家首发，三款减重药物也将于美团平台内上演“三强争霸”。　　凭借“产品+服务”的创新保障模式和大面积...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202507043448631272.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0011963245.USD","symbol_name":"abrdn SICAV I ASIA PACIFIC SUSTAINAB  LE EQUITY \"A\" (USD) ACC","start_time":0,"source_url":"http://finance.eastmoney.com/a/202507043448631272.html","article_id":"2548361404","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2548361404","pubTimestamp":1751620103,"columns":[],"sourceInfo":{"source_id":"stock_eastmoney","name":"东方财富"},"weMediaInfo":null,"summary":"美团又一次成为GLP-1减重药物的首发平台。7月3日，刚刚获批的减重创新药物玛仕度肽注射液（商品名：信尔美?）在美团医药健康旗下美团自营大药房首发上线。对此，专家提醒：购买、用药仍需遵医嘱或在专业药师指导下进行。据悉，这是继口服版司美格鲁肽和替尔泊肽之后，美团又一次承接GLP-1药物的全网独家首发，三款减重药物也将于美团平台内上演“三强争霸”。","collect":0,"end_time":0,"defaultTopTitle":"eastmoney.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0011963245.USD":"abrdn SICAV I ASIA PACIFIC SUSTAINAB  LE EQUITY \"A\" (USD) ACC","HMTD.SI":"Meituan HK SDR 5to1","LU0143863784.USD":"CT (LUX) I GLOBAL EMERGING MARKET EQUITIES\"DU\" (USD) ACC","LU0463099449.HKD":"SCHRODER ISF CHINA OPPORTUNITIES \"A\" (HKD) ACC","IE0008369823.USD":"FSSA HONG KONG GROWTH \"I\" ACC","MPNGY":"美团ADR","LU1993786604.SGD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (SGD) ACC","LU0577902298.EUR":"FULLERTON LUX FUNDS - ASIA GROWTH & INCOME EQUITIE \"I\" (EUR) ACC","LU0509642566.USD":"SCHRODER ISF GLOBAL EMERGING MARKET OPPORTUNITIES \"A\" (USD) INC AV","LU0251144936.SGD":"Fidelity Sustainable Asia Equity A-SGD","LU0326948709.USD":"SCHRODER ISF ASIAN TOTAL RETURN \"A\" (USD) ACC","BK1583":"高瓴概念","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD","LU1328277881.USD":"MANULIFE GF DRAGON GROWTH FUND \"AA\" (USD) INC","LU0541502299.USD":"ALLSPRING  EMERGING MARKETS EQUITY \"I\" (USD) ACC","LU1102505762.USD":"富达新兴市场焦点 A","IE00B29SXG58.USD":"FSSA CHINA FOCUS \"I\" (USD) ACC","BK1521":"挪威政府全球养老基金持仓","LU0499858602.USD":"NINETY ONE GSF ASIA PACIFIC EQUITY OPPORTUNITIES \"A\" (USD) ACC","LU0737861699.HKD":"FIDELITY CHINA FOCUS \"A \" (HKD) ACC","LU0449515922.USD":"HSBC GIF GLOBAL EMERGING MARKETS EQUITY \"PC\" (USD)ACC","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","LU1868838027.USD":"CT (LUX) I GLOBAL EMERGING MARKET EQUITIES \"8\" (USD) ACC","LU1880383366.USD":"东方汇理中国股票基金 A2 (C)","LU0049853897.USD":"SCHRODER ISF EMERGING MARKETS \"A\" (USD) INC AV","IE0034224299.USD":"PINEBRIDGE ASIA EX JAPAN EQUITY \"A\" (USD) ACC","LU0979878070.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"A\" (USD) ACC","LU1880383440.USD":"AMUNDI FUNDS CHINA EQUITY \"A2\" (USD) INC","LU0819121731.USD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"AC\" (USD) ACC","LU0605514214.HKD":"FIDELITY CHINA CONSUMER \"A\" (HKD) ACC","LU0797268264.HKD":"ALLIANZ TOTAL RETURN ASIAN EQUITY \"AT\" (HKD) ACC","BK1589":"北水核心资产","LU0072913022.USD":"UBS (LUX) EQUITY FUND -  GREATER CHINA \"P\" (USD) ACC","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","LU0456827905.SGD":"JPMorgan Funds - China A (acc) SGD","LU0149721374.USD":"HSBC GIF HONG KONG EQUITY \"AD\" INC","LU0594300179.USD":"FIDELITY CHINA CONSUMER \"A\" (USD) ACC","LU0700851271.USD":"NINETY ONE GSF EMERGING MARKETS MULTI-ASSET \"A\" (USD) ACC","LU0417516902.SGD":"Allianz China Equity Cl AT Acc SGD","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","GLP":"Global Partners Lp","LU1105468828.SGD":"Allianz Total Return Asian Equity AM DIS H2-SGD","LU0531971595.HKD":"HSBC GIF CHINESE EQUITY \"AD\" (HKD) INC","LU0871576103.HKD":"HSBC GIF CHINESE EQUITY \"AC\" (HKD) ACC","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","03690":"美团-W","LU1770034418.SGD":"ALL CHINA EQUITY \"A\" (SGDHDG) ACC","BK1610":"ETF&股票定投概念","LU0823040885.USD":"东方汇理新兴市场焦点股票基金"},"translate_title":"The platform staged the \"three strong competition\" of GLP-1 drugs, and China's first GLP-1 weight loss drug was launched online on Meituan","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GLP":1,"METmain":0.6,"HMTD.SI":0.6,"03690":1,"MPNGY":1},"content_text":"美团又一次成为GLP-1减重药物的首发平台。7月3日，刚刚获批的减重创新药物玛仕度肽注射液（商品名：信尔美®）在美团医药健康旗下美团自营大药房首发上线。　　对此，专家提醒：购买、用药仍需遵医嘱或在专业药师指导下进行。　　据悉，这是继口服版司美格鲁肽和替尔泊肽之后，美团又一次承接GLP-1药物的全网独家首发，三款减重药物也将于美团平台内上演“三强争霸”。　　凭借“产品+服务”的创新保障模式和大面积空运履约能力，美团成为GLP-1领域占领一定市场优势的医药电商。为了进一步保障GLP-1在运输过程中的品质，美团自营大药房近期也对运输装备进行了升级。目前采用的专属温控运输箱，不仅能够抵御外部高温辐射，也通过新型缓释型冰盒实现持久控温，全链路实现对药品的控温保质。　　据了解，玛仕度肽可用于成人肥胖或超重患者的长期体重控制，这也是全球首个获批的GCG/GLP-1双受体激动减重药物。该药物此前在全球范围内开展了多项临床研究，有结果显示治疗20周减重降幅最高可达21%。降糖适应证预期也将在不久后获批。　　据行业预测，2025年全球GLP-1药物市场规模将突破600亿美元，中国市场规模预计达45亿美元，年增长率超28%。（文章来源：广州日报）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2548361404","isCrawlerRequest":true}